FindTrial
Sign In

Ethionamide

DRUG3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), University of Cape Town, Michael Hoelscher

Conditions

Extensively-drug Resistant TuberculosisHIV InfectionsMultidrug Resistant TuberculosisOther Specified Pulmonary TuberculosisPulmonary TuberculosisTuberculosis

Phase 2

An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis
CompletedNCT02454205
University of Cape TownExtensively-drug Resistant Tuberculosis, Multidrug Resistant Tuberculosis, Tuberculosis
Start: 2015-11-12End: 2021-08-30Updated: 2021-09-29
PanACEA - STEP2C -01
RecruitingNCT05807399
Michael HoelscherOther Specified Pulmonary Tuberculosis, Pulmonary Tuberculosis
Start: 2023-04-14End: 2027-12-30Target: 390Updated: 2025-10-07

Unknown Phase

A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.
CompletedNCT00000796
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections, Tuberculosis
End: 1998-10-31Target: 525Updated: 2021-11-03

Related Papers

An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study)
American Journal of Respiratory and Critical Care Medicine2022-02-1786 citations
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial
Trials2019-01-1629 citations